{"transactions":[{"id":4638265,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-08T23:55:35.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":3796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders."},{"field":"shares","element":"transactionShares","label":"F2","text":"This Form 4/A amends the Form 4 filed on May 7, 2026 solely to correct the number of RSUs acquired and the amount of securities beneficially owned following the reported transaction. The original filing reported 6,796 RSUs acquired. The correct number of RSUs acquired was 3,796. As a result, the amount of securities beneficially owned following the transaction has been revised accordingly."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This Form 4/A amends the Form 4 filed on May 7, 2026 solely to correct the number of RSUs acquired and the amount of securities beneficially owned following the reported transaction. The original filing reported 6,796 RSUs acquired. The correct number of RSUs acquired was 3,796. As a result, the amount of securities beneficially owned following the transaction has been revised accordingly."}],"balance_after":42294,"source":{"system":"sec-edgar","filing":"0001159036-26-000139","document":"wk-form4a_1791503732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662521/000115903626000139/wk-form4a_1791503732.xml","form_type":"4/A","original_submission_date":"2026-05-07"}},{"id":691048,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:43:57.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":1626,"price":102.8,"value":167152.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."}],"balance_after":40418,"source":{"system":"sec-edgar","filing":"0001662521-26-000002","document":"wk-form4_1786484634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000166252126000002/wk-form4_1786484634.xml","form_type":"4"}},{"id":718806,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:42:08.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":625,"price":77.209,"value":48255.625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.950 to $77.710. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":42044,"source":{"system":"sec-edgar","filing":"0001159036-26-000094","document":"wk-form4_1783024925.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000094/wk-form4_1783024925.xml","form_type":"4"}},{"id":718805,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:42:08.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":76.395,"value":76395.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.930 to $76.850. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":42669,"source":{"system":"sec-edgar","filing":"0001159036-26-000094","document":"wk-form4_1783024925.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000094/wk-form4_1783024925.xml","form_type":"4"}},{"id":730009,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to  buy)","published_at":"2026-06-22T20:31:17.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":51700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027."}],"balance_after":51700,"derivative":{"exercise_price":2.55,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":51700},"source":{"system":"sec-edgar","filing":"0001650664-26-000072","document":"wk-form4_1782160274.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000072/wk-form4_1782160274.xml","form_type":"4"}},{"id":755419,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T21:20:34.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1625,"price":66.21,"value":107591.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."}],"balance_after":43669,"source":{"system":"sec-edgar","filing":"0001159036-26-000072","document":"wk-form4_1780435230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000072/wk-form4_1780435230.xml","form_type":"4"}},{"id":788720,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2026-05-07T23:01:36.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":6040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":6040,"derivative":{"exercise_price":65.87,"expiration_date":"2036-05-05","underlying":"Common Stock","underlying_shares":6040},"source":{"system":"sec-edgar","filing":"0001159036-26-000059","document":"wk-form4_1778194891.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000059/wk-form4_1778194891.xml","form_type":"4"}},{"id":788719,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-07T23:01:36.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":6796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":45294,"source":{"system":"sec-edgar","filing":"0001159036-26-000059","document":"wk-form4_1778194891.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000059/wk-form4_1778194891.xml","form_type":"4"}},{"id":792291,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T21:05:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":1625,"price":63.48,"value":103155.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."}],"balance_after":38498,"source":{"system":"sec-edgar","filing":"0001159036-26-000055","document":"wk-form4_1778015107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000055/wk-form4_1778015107.xml","form_type":"4"}},{"id":947553,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T23:55:55.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":70.25,"value":140500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."}],"balance_after":40123,"source":{"system":"sec-edgar","filing":"0001159036-26-000006","document":"wk-form4_1767743752.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000006/wk-form4_1767743752.xml","form_type":"4"}},{"id":985359,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-02T00:50:47.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":829,"price":71.6,"value":59356.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."}],"balance_after":42123,"source":{"system":"sec-edgar","filing":"0001159036-25-000065","document":"wk-form4_1764636645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000065/wk-form4_1764636645.xml","form_type":"4"}},{"id":1002456,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:58:21.000Z","date":"2025-11-10","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":68.48,"value":136960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."}],"balance_after":42952,"source":{"system":"sec-edgar","filing":"0001159036-25-000052","document":"wk-form4_1762988298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000052/wk-form4_1762988298.xml","form_type":"4"}},{"id":1029629,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-01T22:29:35.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":500,"price":75.704,"value":37852.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share.  The shares were sold at prices ranging from $75.64 to $75.92.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":44952,"source":{"system":"sec-edgar","filing":"0001662521-25-000005","document":"form4-10012025_101031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000166252125000005/form4-10012025_101031.xml","form_type":"4"}},{"id":1029628,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-01T22:29:35.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":75.086,"value":112629.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share.  The shares were sold at prices ranging from $74.64 to $75.55.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":45452,"source":{"system":"sec-edgar","filing":"0001662521-25-000005","document":"form4-10012025_101031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000166252125000005/form4-10012025_101031.xml","form_type":"4"}},{"id":1051777,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T00:11:41.000Z","date":"2025-09-02","kind":"sale","planned":true,"acquired":false,"shares":923,"price":74.111,"value":68404.453,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share.  The shares were sold at prices ranging from $73.95 to $74.38.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":46952,"source":{"system":"sec-edgar","filing":"0001415889-25-023470","document":"form4-09032025_120938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925023470/form4-09032025_120938.xml","form_type":"4"}},{"id":1051776,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T00:11:41.000Z","date":"2025-09-02","kind":"sale","planned":true,"acquired":false,"shares":2977,"price":73.618,"value":219160.786,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share.  The shares were sold at prices ranging from $72.91 to $73.89.  The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":47875,"source":{"system":"sec-edgar","filing":"0001415889-25-023470","document":"form4-09032025_120938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925023470/form4-09032025_120938.xml","form_type":"4"}},{"id":1051775,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T00:11:41.000Z","date":"2025-09-02","kind":"sale","planned":true,"acquired":false,"shares":100,"price":71.71,"value":7171.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."}],"balance_after":50852,"source":{"system":"sec-edgar","filing":"0001415889-25-023470","document":"form4-09032025_120938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925023470/form4-09032025_120938.xml","form_type":"4"}},{"id":1115973,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to  buy)","published_at":"2025-06-10T20:18:24.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026."}],"balance_after":37500,"derivative":{"exercise_price":1.91,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001650664-25-000100","document":"wk-form4_1749586697.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000100/wk-form4_1749586697.xml","form_type":"4"}},{"id":1161471,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2025-05-02T20:02:32.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":5750,"derivative":{"exercise_price":60.03,"expiration_date":"2035-05-01","underlying":"Common Stock","underlying_shares":5750},"source":{"system":"sec-edgar","filing":"0001415889-25-011767","document":"form4-05022025_080528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925011767/form4-05022025_080528.xml","form_type":"4"}},{"id":1161470,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T20:02:32.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":4165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program.  Each RSU represents the right to receive one share of common stock of the Issuer.  This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":50952,"source":{"system":"sec-edgar","filing":"0001415889-25-011767","document":"form4-05022025_080528.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925011767/form4-05022025_080528.xml","form_type":"4"}},{"id":1494752,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to  buy)","published_at":"2024-06-03T20:25:34.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025."}],"balance_after":25000,"derivative":{"exercise_price":5.17,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001650664-24-000056","document":"wk-form4_1717446325.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000056/wk-form4_1717446325.xml","form_type":"4"}},{"id":1533926,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2024-04-29T21:51:24.000Z","date":"2024-04-25","kind":"grant","planned":false,"acquired":true,"shares":8804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":8804,"derivative":{"exercise_price":38.46,"expiration_date":"2034-04-25","underlying":"Common Stock","underlying_shares":8804},"source":{"system":"sec-edgar","filing":"0001415889-24-011679","document":"form4-04292024_090416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011679/form4-04292024_090416.xml","form_type":"4"}},{"id":1533925,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-29T21:51:24.000Z","date":"2024-04-25","kind":"grant","planned":false,"acquired":true,"shares":6501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program.  Each RSU represents the right to receive one share of common stock of the Issuer.  This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":46787,"source":{"system":"sec-edgar","filing":"0001415889-24-011679","document":"form4-04292024_090416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011679/form4-04292024_090416.xml","form_type":"4"}},{"id":1772014,"issuer":{"id":109360,"kind":"organization","name":"Syneos Health, Inc.","symbol":"SYNH"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-09-28T17:05:52.000Z","date":"2023-09-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4863,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the \"Merger Agreement\"), by and among Syneos Health, Inc. (the \"Issuer\"), Star Parent, Inc. (\"Parent\") and Star Merger Sub, Inc. (\"Merger Sub\"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the \"Merger\") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the \"Merger Consideration\"), without interest, and minus any applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the \"Effective Time\") and as a result of the Merger each award of restricted stock units (\"RSUs\") and performance stock units (\"PSUs\") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the \"Specified Awards\")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a \"Contingent Cash Award\") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the \"target\" level of performance or based on the actual level of achievement of performance goals,"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for \"cause\" or by the holder without \"good reason,\" in either case prior to the first anniversary of the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-050772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610950/000120919123050772/doc4.xml","form_type":"4"}},{"id":1772013,"issuer":{"id":109360,"kind":"organization","name":"Syneos Health, Inc.","symbol":"SYNH"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-09-28T17:05:52.000Z","date":"2023-09-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9915,"price":43,"value":426345.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the \"Merger Agreement\"), by and among Syneos Health, Inc. (the \"Issuer\"), Star Parent, Inc. (\"Parent\") and Star Merger Sub, Inc. (\"Merger Sub\"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the \"Merger\") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the \"Merger Consideration\"), without interest, and minus any applicable withholding taxes."}],"balance_after":4863,"source":{"system":"sec-edgar","filing":"0001209191-23-050772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610950/000120919123050772/doc4.xml","form_type":"4"}},{"id":1866070,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-05T20:30:44.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 1, 2023 and is scheduled to vest in full on June 1, 2024."}],"balance_after":25000,"derivative":{"exercise_price":9.55,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-23-009236","document":"form4-06052023_040621.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000141588923009236/form4-06052023_040621.xml","form_type":"4"}},{"id":1874235,"issuer":{"id":109360,"kind":"organization","name":"Syneos Health, Inc.","symbol":"SYNH"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-05-30T17:14:14.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":4863,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the 2024 annual meeting of stockholders but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors."}],"balance_after":14778,"source":{"system":"sec-edgar","filing":"0001209191-23-032940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610950/000120919123032940/doc4.xml","form_type":"4"}},{"id":1899760,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-05-09T22:12:04.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":11371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents annual stock option grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":11371,"derivative":{"exercise_price":31,"exercise_date":"2024-05-05","expiration_date":"2033-05-05","underlying":"Common Stock","underlying_shares":11371},"source":{"system":"sec-edgar","filing":"0001415889-23-007688","document":"form4-05092023_100557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923007688/form4-05092023_100557.xml","form_type":"4"}},{"id":1899759,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-09T22:12:04.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":8065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program.  Each RSU represents the right to receive one share of common stock of the Issuer.  This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.  These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director."}],"balance_after":40286,"source":{"system":"sec-edgar","filing":"0001415889-23-007688","document":"form4-05092023_100557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923007688/form4-05092023_100557.xml","form_type":"4"}},{"id":2112715,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-17T22:10:46.000Z","date":"2022-11-16","kind":"gift","acquired":false,"shares":5998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift to charity."}],"balance_after":32221,"source":{"system":"sec-edgar","filing":"0001415889-22-011511","document":"form4-11172022_101138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588922011511/form4-11172022_101138.xml","form_type":"4"}},{"id":2233634,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T20:30:48.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022 and is scheduled to vest in full on June 9, 2023."}],"balance_after":25000,"derivative":{"exercise_price":12.31,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-22-006494","document":"form4-06132022_040635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000141588922006494/form4-06132022_040635.xml","form_type":"4"}},{"id":2252718,"issuer":{"id":109360,"kind":"organization","name":"Syneos Health, Inc.","symbol":"SYNH"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-05-27T17:03:39.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":2839,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors."}],"balance_after":9915,"source":{"system":"sec-edgar","filing":"0001209191-22-032624","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610950/000120919122032624/doc4.xml","form_type":"4"}},{"id":2279548,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-07T00:04:57.000Z","date":"2022-05-05","kind":"grant","acquired":true,"shares":6206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":38219,"source":{"system":"sec-edgar","filing":"0001179110-22-002907","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022002907/edgar.xml","form_type":"4"}},{"id":2532572,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-10-28T20:13:42.000Z","date":"2021-10-26","kind":"grant","acquired":true,"shares":24732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on October 26, 2021 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on October 26, 2022 through October 26, 2024."}],"balance_after":24732,"derivative":{"exercise_price":37.9,"expiration_date":"2031-10-25","underlying":"Common Stock","underlying_shares":24732},"source":{"system":"sec-edgar","filing":"0001179110-21-009688","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000117911021009688/edgar.xml","form_type":"4"}},{"id":2711841,"issuer":{"id":109360,"kind":"organization","name":"Syneos Health, Inc.","symbol":"SYNH"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-14T17:06:45.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":2364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors."}],"balance_after":7076,"source":{"system":"sec-edgar","filing":"0001209191-21-032806","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610950/000120919121032806/doc4.xml","form_type":"4"}},{"id":2725294,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-05-07T00:01:10.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":5230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2022 and (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":32013,"source":{"system":"sec-edgar","filing":"0001179110-21-004970","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911021004970/edgar.xml","form_type":"4"}},{"id":3130110,"issuer":{"id":109360,"kind":"organization","name":"Syneos Health, Inc.","symbol":"SYNH"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2020-05-29T17:02:44.000Z","date":"2020-05-27","kind":"grant","acquired":true,"shares":2803,"price":62.43,"value":174991.29,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors."}],"balance_after":4712,"source":{"system":"sec-edgar","filing":"0001610950-20-000102","document":"wf-form4_159078614606488.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610950/000161095020000102/wf-form4_159078614606488.xml","form_type":"4"}},{"id":3165556,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-01T23:10:38.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":8829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) April 30, 2021 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":26783,"source":{"system":"sec-edgar","filing":"0001179110-20-005376","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020005376/edgar.xml","form_type":"4"}},{"id":3370974,"issuer":{"id":109360,"kind":"organization","name":"Syneos Health, Inc.","symbol":"SYNH"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2019-11-14T16:22:48.000Z","date":"2019-11-12","kind":"grant","acquired":true,"shares":1909,"price":49.48,"value":94457.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting."}],"balance_after":1909,"source":{"system":"sec-edgar","filing":"0001610950-19-000057","document":"wf-form4_157376655281836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610950/000161095019000057/wf-form4_157376655281836.xml","form_type":"4"}},{"id":3540215,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-03T20:10:08.000Z","date":"2019-05-02","kind":"grant","acquired":true,"shares":12173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock grant under the Issuer's director compensation program.  This grant will vest in full on the earlier of (i) May 2, 2020 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":17954,"source":{"system":"sec-edgar","filing":"0001179110-19-005499","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019005499/edgar.xml","form_type":"4"}},{"id":3819736,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-11T22:24:47.000Z","date":"2018-09-07","kind":"grant","acquired":true,"shares":5781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents initial restricted stock grant upon becoming a member of the Company's Board of Directors pursuant to the Director's Compensation Program.  This grant will vest on the date of the Company's 2019 annual meeting of stockholders."}],"balance_after":5781,"source":{"system":"sec-edgar","filing":"0001179110-18-011307","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018011307/edgar.xml","form_type":"4"}}]}